Liwei Qiu

1.0k total citations
51 papers, 877 citations indexed

About

Liwei Qiu is a scholar working on Molecular Biology, Cancer Research and Hepatology. According to data from OpenAlex, Liwei Qiu has authored 51 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 21 papers in Cancer Research and 12 papers in Hepatology. Recurrent topics in Liwei Qiu's work include Cancer, Hypoxia, and Metabolism (13 papers), Hepatocellular Carcinoma Treatment and Prognosis (10 papers) and Cancer, Lipids, and Metabolism (8 papers). Liwei Qiu is often cited by papers focused on Cancer, Hypoxia, and Metabolism (13 papers), Hepatocellular Carcinoma Treatment and Prognosis (10 papers) and Cancer, Lipids, and Metabolism (8 papers). Liwei Qiu collaborates with scholars based in China, Japan and Greece. Liwei Qiu's co-authors include Dengfu Yao, Min Yao, Zhizhen Dong, Xinhua Wu, Wenli Sai, Xianyong Meng, Haijian Zhang, Dengbing Yao, Wei Wu and Xuanyi Zhou and has published in prestigious journals such as Frontiers in Immunology, World Journal of Gastroenterology and Oncotarget.

In The Last Decade

Liwei Qiu

48 papers receiving 863 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liwei Qiu China 18 427 294 245 165 154 51 877
Junyi He China 19 369 0.9× 197 0.7× 42 0.2× 240 1.5× 73 0.5× 64 1.0k
Xiaofeng Dong China 17 235 0.6× 162 0.6× 60 0.2× 191 1.2× 81 0.5× 51 716
Li Ss China 13 266 0.6× 98 0.3× 54 0.2× 99 0.6× 63 0.4× 28 529
Chenxi Hu China 18 440 1.0× 214 0.7× 18 0.1× 202 1.2× 85 0.6× 65 930
Shan Jin China 17 312 0.7× 219 0.7× 117 0.5× 153 0.9× 101 0.7× 57 796
Yue Jiang China 20 942 2.2× 708 2.4× 19 0.1× 195 1.2× 77 0.5× 72 1.5k
Jiaqi Li China 15 462 1.1× 407 1.4× 13 0.1× 104 0.6× 37 0.2× 70 830
Xinyao Hu China 17 414 1.0× 149 0.5× 9 0.0× 102 0.6× 146 0.9× 61 1.1k
Peiping Li China 13 121 0.3× 102 0.3× 78 0.3× 97 0.6× 56 0.4× 30 422

Countries citing papers authored by Liwei Qiu

Since Specialization
Citations

This map shows the geographic impact of Liwei Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liwei Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liwei Qiu more than expected).

Fields of papers citing papers by Liwei Qiu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liwei Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liwei Qiu. The network helps show where Liwei Qiu may publish in the future.

Co-authorship network of co-authors of Liwei Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Liwei Qiu. A scholar is included among the top collaborators of Liwei Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liwei Qiu. Liwei Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Rui, Qian Liang, Mei Yang, et al.. (2025). Organ-based characterization of B cells in patients with systemic lupus erythematosus. Frontiers in Immunology. 16. 1509033–1509033. 5 indexed citations
2.
Zhao, Suming, Liwei Qiu, Hui Zhao, et al.. (2021). Prognostic nomogram for hepatocellular carcinoma patients after transarterial chemoembolization based on des-γ-carboxy prothrombin reactivity and modified Response Evaluation Criteria in Solid Tumors. Journal of Cancer Research and Therapeutics. 17(3). 707–714. 8 indexed citations
3.
Qiu, Liwei, Yifei Liu, Xiaoqing Cao, et al.. (2020). Annexin A2 promotion of hepatocellular carcinoma tumorigenesis via the immune microenvironment. World Journal of Gastroenterology. 26(18). 2126–2137. 30 indexed citations
4.
Wang, Xia, et al.. (2017). MicroRNA-30c inhibits metastasis of ovarian cancer by targeting metastasis-associated gene 1. Journal of Cancer Research and Therapeutics. 13(4). 676–676. 6 indexed citations
5.
Zhang, Haijian, Min Yao, Wei Wu, et al.. (2015). Up-regulation of annexin A2 expression predicates advanced clinicopathological features and poor prognosis in hepatocellular carcinoma. Tumor Biology. 36(12). 9373–9383. 35 indexed citations
6.
Zheng, Wenjie, Min Yao, Wenli Sai, et al.. (2015). Diagnostic and prognostic significance of secretory clusterin expression in patients with hepatocellular carcinoma. Tumor Biology. 37(1). 999–1008. 17 indexed citations
7.
Yao, Min, Li Wang, Liwei Qiu, Qi Qian, & Dengfu Yao. (2015). Encouraging microRNA-based Therapeutic Strategies for Hepatocellular Carcinoma. Anti-Cancer Agents in Medicinal Chemistry. 15(4). 453–460. 9 indexed citations
8.
Yao, Min, Wenjie Zheng, Xuli Yang, et al.. (2015). Abnormality of Wnt3a expression as novel specific biomarker for diagnosis and differentiation of hepatocellular carcinoma. Tumor Biology. 37(4). 5561–5568. 16 indexed citations
9.
Sai, Wenli, Li Wang, Wenjie Zheng, et al.. (2015). Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepatitis Monthly. 15(12). e32918–e32918. 18 indexed citations
10.
Yu, Dandan, Min Yao, Jie Chen, et al.. (2013). [Short hairpin RNA mediated glypican-3 silencing inhibits hepatoma cell invasiveness and disrupts molecular pathways of angiogenesis].. PubMed. 21(6). 452–8. 2 indexed citations
11.
Yao, Min, Dengfu Yao, Yinzhu Bian, et al.. (2013). Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary & pancreatic diseases international. 12(2). 171–179. 40 indexed citations
12.
Yao, Ninghua, Dengfu Yao, Li Wang, et al.. (2012). Inhibition of autocrine IGF-II on effect of human HepG2 cell proliferation and angiogenesis factor expression. Tumor Biology. 33(5). 1767–1776. 23 indexed citations
13.
Yu, Dandan, Zhizhen Dong, Min Yao, et al.. (2012). Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA. Tumor Biology. 34(2). 661–668. 12 indexed citations
14.
Li, Shanshan, Dengfu Yao, Li Wang, et al.. (2011). Expression characteristics of HIF-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepatitis Monthly. 11(10). 821–828. 41 indexed citations
15.
Qian, Jing, Dengfu Yao, Zhizhen Dong, et al.. (2010). Characteristics of Hepatic IGF-II Expression and Monitored Levels of Circulating IGF-II mRNA in Metastasis of Hepatocellular Carcinoma. American Journal of Clinical Pathology. 134(5). 799–806. 40 indexed citations
16.
Wu, Wei, Dengfu Yao, Yilang Wang, et al.. (2010). Suppression of human hepatoma (HepG2) cell growth by nuclear factor-kappaB/p65 specific siRNA. Tumor Biology. 31(6). 605–611. 11 indexed citations
17.
Dong, Zhizhen, Dengfu Yao, Wei Wu, et al.. (2010). Delayed hepatocarcinogenesis through antiangiogenic intervention in the nuclear factor-kappa B activation pathway in rats.. PubMed. 9(2). 169–74. 10 indexed citations
18.
Qiu, Liwei, Dengfu Yao, Lei Zong, et al.. (2008). Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development.. PubMed. 7(4). 406–11. 18 indexed citations
19.
Wu, Wei, Dengfu Yao, Xiaohua Li, et al.. (2006). Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.. PubMed. 5(4). 538–44. 21 indexed citations
20.
Wu, Wei, Dengfu Yao, Liwei Qiu, et al.. (2005). Abnormal expression of hepatomas and circulating telomerase and its clinical values.. PubMed. 4(4). 544–9. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Junyi He Breakdown of academic impact, for papers by Xiaofeng Dong Breakdown of academic impact, for papers by Li Ss Breakdown of academic impact, for papers by Chenxi Hu Breakdown of academic impact, for papers by Shan Jin Breakdown of academic impact, for papers by Yue Jiang Breakdown of academic impact, for papers by Jiaqi Li Breakdown of academic impact, for papers by Xinyao Hu Breakdown of academic impact, for papers by Peiping Li
Rankless by CCL
2026